David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, previews the American Academy of Neurology (AAN) annual meeting for 2023 and says that attendees can expect not only to learn but also to leave feeling humbled and inspired.
Attendees can expect to leave the American Academy of Neurology (AAN) 75th annual meeting humbled and inspired, while participating in high-quality programming along the way, says David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University.
Transcript
What can attendees look forward to at the AAN 2023 Annual Meeting?
The AAN has always been one of my favorite meetings to go to. I've been going pretty regularly for the last 20 years or so. I think people correctly think about it as being the premier place to go for cutting-edge research and hearing about what's hot off the press in neurology, which is correct.
They also have amazing educational programs, so that's been one of the things that I've really enjoyed going to. I work in a specialized field, so it's an opportunity to learn about things that I don't see every day. And the quality of the programming for education is really, really high.
I think also there's still a little bit of pent-up postpandemic need to get together and see people. So, it's always fun, at an in-person meeting, to just run across somebody in the hallway you haven't seen for a couple of years, meet up with people who are working in a similar area, and identify people who are potential collaborators and researchers in the future.
I always leave and have a mix of being humbled about everything that's happening that I'm not doing and inspired by a lot of new ideas.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More